THE WOODLANDS, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that company management, including Mike Exton, Lexicon’s chief executive officer ...

On Wednesday, Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $0.8 which represents a decrease of $-0.02 or -2.44% from the prior close of $0.82. The stock opened at $0.81 ...

Lexicon completes patient enrollment in phase 2B PROGRESS study of LX9211 in diabetic peripheral neuropathic pain: The Woodlands, Texas Thursday, November 28, 2024, 12:00 Hrs [IST ...

Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre, Phase IIb PROGRESS trial of the new ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

Derm-Biome Pharmaceuticals added Dr. Jerry Tan to its scientific advisory board. Lexicon Pharmaceuticals added former Eisai ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...

Lexicon Pharmaceuticals is shifting focus to its late-stage pipeline following the FDA's rejection of Zynquista for type 1 ...

Needham & Company LLC reaffirmed their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX – Free Report) in a research note published on Friday,Benzinga reports. LXRX has been the subject ...

Detailed price information for Lexicon Pharmaceutcl (LXRX-Q) from The Globe and Mail including charting and trades.

For many biopharmas, it takes years of hard work to transition from being a clinical-stage drugmaker to a commercial one.

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application ...